Factors affecting the free plasma fraction of phenytoin in patients with epilepsy

Clinical Drug Investigation

Volumn 15, Issue 2, 1998, Pages 153-157

  Jiménez, Manuel Carlos ^a   Durán, José Antonio ^a,b   Abadín, José Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b Facultad de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; PHENYTOIN; PLASMA PROTEIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EPILEPSY; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENDER; HUMAN; HYPOALBUMINEMIA; INFANT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ULTRAFILTRATION; UREMIA;

EID: 0031886111     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815020-00008     Document Type: Article

References (21)

1. Gannaway DJ, Mawer GE. Serum phenytoin concentration and clinical response in patients with epilepsy. Br J Clin Pharmacol 1981; 12: 833-9
2. Cobos JE. High-dose phenytoin in the treatment of refractory epilepsy. Epilepsia 1987; 28: 111-4
3. Perucca E, Richens A. Antiepileptic drugs: clinical aspects. In: Richens A, Marks V, editors. Therapeutic drug monitoring. London: Churchill Livingstone, 1981; 321-48
4. Peterson GM, McLean S, Aldous S, et al. Plasma protein hinding of phenytoin in 100 epileptic patients. Br J Clin Pharmacol 1982; 14: 298-300
5. Levy RH, Schmidt D. Utility of free level monitoring of antiepileptic drugs. Epilepsia 1985; 26: 199-205
6. Perucca E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther Drug Monit 1980; 2: 331-44
7. Johno I, Kuzuya T, Suzuki K, et al. Is free fraction measurement of phenytoin always necessary in paediatric epileptic patients? Ther Drug Monit 1988; 10: 39-44
8. Barth N, Alvan G, Borga O, et al. Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet 1976; 1: 444-52
9. Rimmer EM, Buss DC, Routledge PA, et al. Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmacol 1984; 17: 99-102
10. Kilpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of phenytoin in the management of epilepsy. Br J Clin Pharmacol 1984; 17: 539-46
11. Sallustio BC, Morris RC. Unbound plasma phenytoin concentrations measured using enzyme immunoassay technique on the Cohas MIRA Analyser. In vivo effect of valproic acid. Ther Drug Monit 1992; 14: 9-13
12. Hooper WD, Bochner F, Eadie MJ, et al. Plasma protein binding of diphenylhydantoin. Effects of hormones, renal and hepatic disease. Clin Pharmacol Ther 1974; 15: 276-82
13. Pospisil J, Perlik F. Binding parameters of phenytoin during monotherapy and polytherapy. Int J Clin Pharmacol Ther Toxicol 1992; 30: 24-8
14. Oshima T, Hasegama T, Johno I, et al. Variations in protein binding of drugs in plasma and serum. Clin Chem 1989; 35: 1722-5
15. Peterson GM, Khoo BHC, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991; 13: 415-9
16. Yaffe SJ. Drug protein binding in young children. In: Reidemberg MM, Erill S. editors. Drug protein binding. New York: Praeger. 1986; 153-62
17. Perucca E, Hebdige S, Frigo GM. et al. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980; 28: 779-89
18. Perucca E. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. Clin Pharmacokinet 1984; 9: 71-8
19. Tiula E, Neuvonen PJ. Effect of total drug concentration on the free fraction in uraemic sera. Ther Drug Monit 1986; 8: 27-31
20. Reidemberg MM, Odar-Cederlöf I, Von Bahr C, et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971; 285: 264-7
21. Beringer PM, Rho JP. Is routine measurement of free phenytoin concentration rational? Ther Drug Monit 1995; 17: 381-2